Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Financing

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Sep 30, 2024 9:14pm

113 Views

Post# 36247600

RE:Financing

What these bozos should be doing is setting up a 100% owned subsidiary (e.g. Sirona Laboratories Inc.) that holds an exclusive worldwide license to make and market GPM products. Then seek equity investors for it so that the equity can valued at a reasonable valuation instead of the current ridiculous SBM share price.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”